ALTEOGEN (196170) 44th Annual J.P. Morgan Healthcare Conference Presentation summary

Company overview and milestones

• Focuses on next-generation biologics to improve quality of life, established in 2008 and listed on KOSDAQ.

• Achieved key milestones: IPO, first Hybrozyme licensing, Tergase approval, and EYLUXVI approval in Europe.

• Subsidiary integration and multiple regulatory submissions and approvals for biosimilars and biobetters.

Core technology platforms

• Hybrozyme enables large-volume subcutaneous delivery and is licensed to major pharma companies.

• NexP offers long-acting biobetter technology, licensed for weekly hGH.

• NexMab provides site-specific ADC conjugation for blockbuster ADC products.

Pipeline and product development

• Robust pipeline includes approved Tergase, Herceptin biosimilar, Eylea biosimilar, and ALT-B4 for SC conversion.

• ALT-B4 (berahyaluronidase alfa) shows enhanced stability, higher activity, and lower immunogenicity.

• New technology platforms target once-monthly drug delivery and long-acting formulations.